Henry Schein (NASDAQ:HSIC) Announces Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Henry Schein (NASDAQ:HSIC) posted its quarterly earnings data on Tuesday. The company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.16 by $0.06, Briefing.com reports. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The business had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.24 billion. During the same quarter in the previous year, the firm posted $1.32 earnings per share. Henry Schein’s quarterly revenue was up .4% on a year-over-year basis. Henry Schein updated its FY 2024 guidance to 4.740-4.820 EPS.

Henry Schein Price Performance

Shares of NASDAQ:HSIC traded up $0.91 during midday trading on Wednesday, reaching $69.90. 759,511 shares of the company were exchanged, compared to its average volume of 1,345,775. The company has a current ratio of 1.55, a quick ratio of 0.90 and a debt-to-equity ratio of 0.46. The business’s fifty day moving average is $70.60 and its two-hundred day moving average is $69.78. Henry Schein has a one year low of $62.05 and a one year high of $82.63. The stock has a market cap of $8.86 billion, a PE ratio of 25.94, a price-to-earnings-growth ratio of 2.02 and a beta of 0.87.

Wall Street Analyst Weigh In

Several research firms recently commented on HSIC. Baird R W raised shares of Henry Schein from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 22nd. Barrington Research reiterated an “outperform” rating and issued a $82.00 target price on shares of Henry Schein in a research note on Friday, September 20th. Robert W. Baird dropped their target price on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Evercore ISI upped their target price on shares of Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 8th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Henry Schein presently has an average rating of “Hold” and a consensus price target of $77.50.

Insider Buying and Selling

In other Henry Schein news, SVP Lorelei Mcglynn sold 21,035 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the transaction, the senior vice president now owns 71,833 shares in the company, valued at $4,978,026.90. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.14% of the stock is owned by company insiders.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.